About RecombiMAb anti-mouse CD16/CD32 (LALA-PG) The 2.4G2-CP026 monoclonal antibody is a chimeric version of the original 2.4G2 antibody. The variable domain sequences are identical to the original 2.4G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. The 2.4G2-CP026 antibody also contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. 2.4G2-CP026 reacts specifically with mouse CD16 (FcγRIII) and CD32 (FcγRII). It has also been reported to react non-specifically via its Fc domain to FcγRI. CD16 and CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. These receptors bind to the Fc portion of antibody-antigen complexes and play a role in adaptive immune responses. The 2.4G2 antibody is commonly used in flow cytometry staining experiments to prevent non-specific binding of IgG to the FcγIII and FcγII, and possibly FcγI, receptors prior to staining with antigen specific primary antibodies. The Fab fragments of the 2.4G2 antibody have also been used to block Fc receptors in vivo. RecombiMAb anti-mouse CD16/CD32 (LALA-PG) Specifications IsotypeMouse IgG2a, κ Recommended Isotype Control(s)RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenBALB/c mouse macrophage cell line J774 Reported Applicationsin vivo Fc receptor blocking* Fc receptor blocking, flow cytometry* Fc receptor blocking, immunofluorescence* *Reported for the original rat IgG2b 2.4G2 antibody FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from HEK293 cell supernatant in an animal-free facility PurificationProtein G Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
